Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Sumatriptan Does Not Antagonize CGRP-Induced Symptoms in Healthy Volunteers

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Intravenous Endothelin-1 Infusion Does Not Induce Aura or Headache in Migraine Patients With Aura

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The Stereotypical Image of a Person With Migraine According to Mass Media

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Two-Hour CGRP Infusion Causes Gastrointestinal Hyperactivity: Possible Relevance for CGRP Antibody Treatment

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Functional gene networks reveal distinct mechanisms segregating in migraine families

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Low frequency activation of the sphenopalatine ganglion does not induce migraine-like attacks in migraine patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. No central action of CGRP antagonising drugs in the GTN mouse model of migraine

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Genetic identification of cell types underlying brain complex traits yields insights into the etiology of Parkinson’s disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

OBJECTIVE: Previous attempts to develop a pragmatic human model for testing new anti-migraine drugs, have failed. Calcitonin gene-related peptide (CGRP) induces a mild headache in healthy volunteers and migraine-like headache in migraine patients. The induced headache must respond to already established migraine treatment for validation. Thus, the objective of the study was to test the effect of sumatriptan against CGRP-induced symptoms in an attempt to validate CGRP-induced headache as a model for drug testing.

METHODS: Thirty healthy volunteers were recruited to receive a 2-hour infusion of CGRP on 2 separate days. The participants were pretreated with sumatriptan 1 day and with placebo the other day in a randomized double-blind cross-over fashion. During the infusion, a questionnaire about headache and side effects was administered. Electrocardiography, heart rate, blood pressure, dermal blood flow, and diameter of peripheral arteries were monitored during the infusion. Participants were carefully instructed to fill out a headache questionnaire at home until 12 hours after the infusion start. Primary endpoints are difference between the sumatriptan day and the placebo day in area under the headache score curve (AUC) 0-2 hours after infusion start and in headache intensity 2 hours after infusion start. The study was conducted at the Danish Headache Center in Glostrup, Denmark.

RESULTS: CGRP-induced headache in 86% (25/29) of the participants on the sumatriptan day and in 96% (28/29) of the participants on the placebo day. There was no difference in AUCheadache, 0-2 hours between the days (P = .794). There was a statistically significant decrease in mean atrial pressure (MAP) over time on both days with a16.2% reduction on the sumatriptan day and a 14.8% reduction on the placebo day (P < .001) and a statistically significant increase in heart rate (HR) over time on both days (from mean 57.5 at baseline to mean 105.4 at 120 minutes on the sumatriptan day and from mean 60.2 at baseline to 105.8 at 120 minutes on the placebo day, P < .001). The diameter of peripheral arteries increased statistically significant on both days (P < .001).

CONCLUSION: Sumatriptan does not influence headache score, accompanying symptoms or other symptoms induced by CGRP. Furthermore, a 2-hour CGRP infusion causes a wide range of side effects and does not induce more headache than the usual 20-minute infusion. Thus, the prolonged infusion of CGRP in healthy volunteers is not a valid and pragmatic model for testing new anti-migraine drugs.

OriginalsprogEngelsk
TidsskriftHeadache
Vol/bind60
Udgave nummer4
Sider (fra-til)665-676
Antal sider12
ISSN0017-8748
DOI
StatusUdgivet - apr. 2020

Bibliografisk note

© 2020 American Headache Society.

ID: 59483177